Divarasib vs HBI-2438

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline

Divarasib

Developed by Roche

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT06497556 · Phase 3 · active, not recruiting

The trial is randomized with a real active comparator (sotorasib or adagrasib) and a hard clinical endpoint (progression-free survival), and it reportedly met that endpoint with a statistically significant benefit. However, the study is open-label with no blinding of participants or investigators, which limits confidence in outcome assessment despite blinded independent central review of scans, so it falls short of the strongest tier of evidence.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2026 · NCT04302025 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (Up to approximately 4 years): Krascendo 1 (NCT06497556): divarasib met its primary endpoint (PFS) and key secondary endpoint (OS) vs sotorasib/adagrasib, described as clinically meaningful and statistically significant improvements. (met)

Result source: NCT06497556

HBI-2438

Developed by HUYABIO International, LLC.

Phase 1 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05485974 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDivarasibHBI-2438
PFS, median—Trial running · NCT03178552—Not reported
OS, median—Trial running · NCT03178552—Not reported
ORR—Trial running · NCT03178552—Not reported
Duration of response, median—Trial running · NCT03178552—Not reported

PFS, median

Divarasib
—Trial running · NCT03178552
HBI-2438
—Not reported

OS, median

Divarasib
—Trial running · NCT03178552
HBI-2438
—Not reported

ORR

Divarasib
—Trial running · NCT03178552
HBI-2438
—Not reported

Duration of response, median

Divarasib
—Trial running · NCT03178552
HBI-2438
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HBI-2438: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Divarasib
Krascendo 1 (NCT06497556): divarasib met its primary endpoint (PFS) and key secondary endpoint (OS) vs sotorasib/adagrasib, described as clinically meaningful and statistically significant improvements. NCT06497556 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divarasib's landscape · HBI-2438's landscape